Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Isomorphic Labs, the AI drug-discovery platform spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C round. The London-based company plans to use the capital to push its AI-designed drug candidates into clinical trials. The raise ranks among the largest in AI-biotech and signals continued investor appetite for applying machine learning to cut drug-development timelines and costs. Isomorphic has not disclosed which programs will enter trials first or the round's valuation. Next, watch for trial starts and partnerships with large pharma, which would test whether AI discovery translates into clinical results.
Muhabbit's AI wrote this summary in its own words from TechCrunch's report. It can get details wrong, so check the source.
Named in this story
Isomorphic Labs, Google DeepMind